WO2024056909 - IFN-LAMBDA AS THERAPEUTIC TARGET IN YELLOW FEVER HAEMORRHAGIC FEVER
National phase entry is expected:
Publication Number
WO/2024/056909
Publication Date
21.03.2024
International Application No.
PCT/EP2023/075588
International Filing Date
18.09.2023
Title **
[English]
IFN-LAMBDA AS THERAPEUTIC TARGET IN YELLOW FEVER HAEMORRHAGIC FEVER
[French]
IFN-LAMBDA UTILISÉ EN TANT QUE CIBLE THÉRAPEUTIQUE DANS UNE FIÈVRE HÉMORRAGIQUE DE LA FIÈVRE JAUNE
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
DALLMEIER, Kai
MA, Ji
NEYTS, Johan
Priority Data
22196146.9
16.09.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1882 | |
| EPO | Filing, Examination, Granting | 8131 | |
| Japan | Filing, Examination, Granting | 1976 | |
| South Korea | Filing, Examination, Granting | 1685 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,414
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to the treatment of a viral infection, wherein an interferon lambda or its receptor is inhibited.[French]
L'invention concerne le traitement d'une infection virale, un interféron lambda ou son récepteur étant inhibés.